Brii Biosciences Limited (2137.HK)
- Previous Close
1.090 - Open
1.090 - Bid 1.160 x --
- Ask 1.170 x --
- Day's Range
1.080 - 1.170 - 52 Week Range
0.850 - 4.290 - Volume
2,870,500 - Avg. Volume
4,528,563 - Market Cap (intraday)
846.087M - Beta (5Y Monthly) 1.62
- PE Ratio (TTM)
-- - EPS (TTM)
-0.260 - Earnings Date Mar 25, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
4.78
Brii Biosciences Limited engages in the research and development of therapies for the treatment of infectious and central nervous system diseases primarily in China and the United States. The company develops BRII-179, BRII-835, and BRII-877, which are in Phase 2 the development of a functional cure for HBV for Hepatitis B; BRII-179, a recombinant protein-based HBV immunotherapeutic candidate that is in Phase 2; and BRII-732 that is in Phase 1 clinical trail and BRII-753, which is in preclinical stage for the treatment of HIV. It also develops BRII-296 for the treatment of PPD/MDD, anxiety, and other depressive disorders; BRII-297 for treatment of various depressive disorders; BRII-636, BRII-672, and BRII-693 for the treatment of multi-drug resistant/extensive drug resistant (MDR/XDR) gram-negative infections; and BRII-658 for oral treatment for patients with chronic NTM lung disease. The company was incorporated in 2017 and is headquartered in Beijing, China.
www.briibio.comRecent News: 2137.HK
Performance Overview: 2137.HK
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 2137.HK
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 2137.HK
Valuation Measures
Market Cap
846.09M
Enterprise Value
-2.03B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
1.27k
Price/Book (mrq)
0.25
Enterprise Value/Revenue
-3.28k
Enterprise Value/EBITDA
12.04
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-10.33%
Return on Equity (ttm)
-5.92%
Revenue (ttm)
55.89M
Net Income Avi to Common (ttm)
-174.83M
Diluted EPS (ttm)
-0.260
Balance Sheet and Cash Flow
Total Cash (mrq)
2.66B
Total Debt/Equity (mrq)
0.10%
Levered Free Cash Flow (ttm)
--
Research Analysis: 2137.HK
Analyst Price Targets
Fair Value
No Fair Value available for this ticker
Company Insights: 2137.HK
2137.HK does not have Company Insights